Rizzon P, Scrutinio D, Mangini S G, Lagioia R, de Toma L
Eur Heart J. 1986 Jan;7(1):67-76. doi: 10.1093/oxfordjournals.eurheartj.a061960.
Twenty-nine patients with angina at rest took part in a randomized placebo-controlled short-term study to assess the relative effectiveness of different dosages of nifedipine (N), verapamil (V) and isosorbide dinitrate (ISDN) versus placebo and to evaluate the antianginal effects of a sustained-release preparation of ISDN (sr), of N retard form (r) and of V retard form (r). The 29 patients were divided into 3 groups: the first group of patients (10 patients, group A) was treated with N 10 mg six times daily, V 80 mg three times daily and ISDN 10 mg six times daily; the second group of patients (9 patients, group B) was treated with N 20 mg six times daily, V 120 mg four times daily and ISDN 20 mg six times daily; the third group of patients (10 patients, group C) was treated with N r 20 mg four times daily, V r 120 mg three times daily and ISDN sr 40 mg four times daily. The daily frequency of ischaemic episodes (IE) was assessed by Holter monitoring. The effect of each drug on the mean frequency of IE was compared with the placebo using a one-way analysis of variance and the Newman-Keuls test. In group A, the mean daily frequency of IE per patient was 8.1 +/- 5.9 with the placebo, 1.4 +/- 1.9 with N (P less than 0.001; -82%), 4 +/- 3.6 with V (P: NS; -50%) and 4.3 +/- 3.6 with ISDN (P: NS; -46%). In group B it was 6.4 +/- 3.4 with the placebo, 0.5 +/- 1.6 with N (P less than 0.01; -91%), 0.3 +/- 0.5 with V (P less than 0.01; -95%) and 1.2 +/- 1 with ISDN (P less than 0.01; -82%). In group C it was 10.3 +/- 8.7 with the placebo, 0.7 +/- 1.6 with N r (P less than 0.01; -93%), 1 +/- 2.5 with V r (P less than 0.01; -90%) and 5.1 +/- 7.7 with ISDN sr (P: NS; -50%). In group A a reduction of 100% in the number of recorded IEs was achieved in 5/10 patients by using N, in none by V, and in 1/10 by ISDN. In group B, in 8/9 patients by N, in 6/9 by V and in 3/9 by ISDN. In group C, in 8/10 patients by both N r and V r in 4/10 patients by ISDN sr.(ABSTRACT TRUNCATED AT 400 WORDS)
29例静息型心绞痛患者参与了一项随机、安慰剂对照的短期研究,以评估不同剂量的硝苯地平(N)、维拉帕米(V)和硝酸异山梨酯(ISDN)相对于安慰剂的相对有效性,并评价ISDN缓释制剂(sr)、N缓释剂型(r)和V缓释剂型(r)的抗心绞痛作用。这29例患者被分为3组:第一组患者(10例,A组)接受N 10毫克每日6次、V 80毫克每日3次和ISDN 10毫克每日6次的治疗;第二组患者(9例,B组)接受N 20毫克每日6次、V 120毫克每日4次和ISDN 20毫克每日6次的治疗;第三组患者(10例,C组)接受N r 20毫克每日4次、V r 120毫克每日3次和ISDN sr 40毫克每日4次的治疗。通过动态心电图监测评估每日缺血发作(IE)的频率。使用单因素方差分析和纽曼-基尔斯检验将每种药物对IE平均频率的影响与安慰剂进行比较。在A组中,每名患者IE的平均每日频率在使用安慰剂时为8.1±5.9,使用N时为1.4±1.9(P<0.001;降低82%),使用V时为4±3.6(P:无显著性差异;降低50%),使用ISDN时为4.3±3.6(P:无显著性差异;降低46%)。在B组中,使用安慰剂时为6.4±3.4,使用N时为0.5±1.6(P<0.01;降低91%),使用V时为0.3±0.5(P<0.01;降低95%),使用ISDN时为1.2±1(P<0.01;降低82%)。在C组中,使用安慰剂时为10.3±8.7,使用N r时为0.7±1.6(P<0.01;降低93%),使用V r时为1±2.5(P<0.01;降低90%),使用ISDN sr时为5.1±7.7(P:无显著性差异;降低50%)。在A组中,10例患者中有5例使用N使记录的IE数量减少100%,使用V无患者减少,使用ISDN有1例减少。在B组中,9例患者中有8例使用N减少,6例使用V减少,3例使用ISDN减少。在C组中,10例患者中有8例使用N r和V r减少,4例使用ISDN sr减少。(摘要截短于400字)